Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.

作者: Paul S. Papavasiliou , George C. Cotzias , Simone E. Düby , Andreas J. Steck , Clas Fehling

DOI: 10.1056/NEJM197201062860102

关键词:

摘要: Abstract The clinical state achieved with levodopa was compared to that on plus alpha-methyldopa hydrazine, which blocks conversion of dopamine within peripheral tissues only. Five children dystonia remained unimproved by either regimen. In 26 adults Parkinsonism less needed for symptomatic control when given inhibitor than used alone. amount had be added similar doses in patients who received chronically. Rapid induction therapy, better diurnal and a new capability administer pyridoxine receiving constituted advantages adding levodopa. main disadvantage these combinations the rapid involuntary movements.

参考文章(29)
Victor J. Lotti, Curt C. Porter, POTENTIATION AND INHIBITION OF SOME CENTRAL ACTIONS OF L(—)-DOPA BY DECARBOXYLASE INHIBITORS Journal of Pharmacology and Experimental Therapeutics. ,vol. 172, pp. 406- 415 ,(1970)
FLETCHER MCDOWELL, Treatment of Parkinson's Syndrome with L Dihydroxyphenylalanine (Levodopa) Annals of Internal Medicine. ,vol. 72, pp. 29- 35 ,(1970) , 10.7326/0003-4819-72-1-29
George C. Cotzias, Blocking the Negative Effects of Pyridoxine on Patients Receiving Levodopa JAMA: The Journal of the American Medical Association. ,vol. 215, pp. 1504- 1505 ,(1971) , 10.1001/JAMA.1971.03180220084025
Herbert H. Cornish, The Role of Vitamin b6 in the Toxicity of Hydrazines Annals of the New York Academy of Sciences. ,vol. 166, pp. 136- 145 ,(1969) , 10.1111/J.1749-6632.1969.TB54264.X
Vincenzo Bonavita, The reaction of pyridoxal 5-phosphate with cyanide and its analytical use. Archives of Biochemistry and Biophysics. ,vol. 88, pp. 366- 372 ,(1960) , 10.1016/0003-9861(60)90252-6
Ismael Mena, Jaime Court, Sergio Fuenzalida, Paul S. Papavasiliou, George C. Cotzias, Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane. The New England Journal of Medicine. ,vol. 282, pp. 5- 10 ,(1970) , 10.1056/NEJM197001012820102
G. BARTHOLINI, A. PLETSCHER, Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine. Journal of Pharmacy and Pharmacology. ,vol. 21, pp. 323- 324 ,(2011) , 10.1111/J.2042-7158.1969.TB08258.X
George C. Cotzias, Autoimmunity in Patients Treated With Levodopa JAMA: The Journal of the American Medical Association. ,vol. 207, pp. 1353- 1354 ,(1969) , 10.1001/JAMA.1969.03150200119022
T.L. Sourkes, Inhibition of dihydroxyphenylalanine decarboxylase by derivatives of phenylalanine Archives of Biochemistry and Biophysics. ,vol. 51, pp. 444- 456 ,(1954) , 10.1016/0003-9861(54)90500-7
Richard L. Golden, Levodopa, Pyridoxine, and The Burning Feet Syndrome JAMA: The Journal of the American Medical Association. ,vol. 213, pp. 628- 628 ,(1970) , 10.1001/JAMA.1970.03170300072030